The most read stories in March

By Staff Reporter

- Last updated on GMT

(Image: Getty/Bedo)
(Image: Getty/Bedo)

Related tags: Teva, Pfizer, Astrazeneca, Excipients, Camber Pharmaceuticals, Macleods

After the M&A excitement that began the year, the developments in March were a mixture of long-running events, such as the sartan manufacturing issues, breakthrough research and regulatory struggles.

Catch up on the stories that caught the attention of our readers here:

1. Long-standing issues result in warning letter for Teva

Repeat observations for Teva’s facility resulted in the US Food and Drug Administration issuing a warning letter, citing ‘inadequate oversight and control by executive management’.

2. AstraZeneca cuts 94 jobs from UK campus

It was revealed that the Anglo-Swedish company would cut a number of positions from its Macclesfield, UK, site by 2020, after GMB Union stated it had been involved in negotiations.

3. Pfizer licenses immune tolerance therapy for type 1 diabetes

Pfizer exercised an option from a previous agreement with AnTolRx to develop and license an immune tolerance therapy for type 1 diabetes.

4. Researchers call on manufacturers to provide excipient allergy info

A study carried out by MIT researchers found that 93% of medications contain excipients with the potential to cause an allergic reaction, resulting in a call for greater allergy information.

5. Sartan issues continue as Macleods and Camber issue recalls

Camber and Macleods voluntarily recalled lots of losartan tablets, after trace amounts of a possible carcinogen was found in an API ingredient manufactured at the same third-party facility.

Related topics: Regulatory & Safety

Related news